ADTX
ADiTx Therapeutics, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.
Market Cap: 30.7 Million
Primary Exchange: NASDAQ
Website: http://www.aditxt.com
Shares Outstanding: 5.17 Million
Float: 1.1 Million
Dividend: (%)
Beta: -3.29927997802116
Sector: Health Technology
Industry: Biotechnology
Ethical Flags
Longest drawdown: 16 trading days
From: 2020-07-01 To: 2020-07-24
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|